201 related articles for article (PubMed ID: 18373975)
1. The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells.
Schramme A; Abdel-Bakky MS; Kämpfer-Kolb N; Pfeilschifter J; Gutwein P
Biochem Biophys Res Commun; 2008 May; 370(2):311-6. PubMed ID: 18373975
[TBL] [Abstract][Full Text] [Related]
2. Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin.
Scholz F; Schulte A; Adamski F; Hundhausen C; Mittag J; Schwarz A; Kruse ML; Proksch E; Ludwig A
J Invest Dermatol; 2007 Jun; 127(6):1444-55. PubMed ID: 17363916
[TBL] [Abstract][Full Text] [Related]
3. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein.
Gutwein P; Abdel-Bakky MS; Schramme A; Doberstein K; Kämpfer-Kolb N; Amann K; Hauser IA; Obermüller N; Bartel C; Abdel-Aziz AA; El Sayed el SM; Pfeilschifter J
Am J Pathol; 2009 Jun; 174(6):2061-72. PubMed ID: 19435795
[TBL] [Abstract][Full Text] [Related]
4. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16.
Gough PJ; Garton KJ; Wille PT; Rychlewski M; Dempsey PJ; Raines EW
J Immunol; 2004 Mar; 172(6):3678-85. PubMed ID: 15004171
[TBL] [Abstract][Full Text] [Related]
5. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10.
Abel S; Hundhausen C; Mentlein R; Schulte A; Berkhout TA; Broadway N; Hartmann D; Sedlacek R; Dietrich S; Muetze B; Schuster B; Kallen KJ; Saftig P; Rose-John S; Ludwig A
J Immunol; 2004 May; 172(10):6362-72. PubMed ID: 15128827
[TBL] [Abstract][Full Text] [Related]
6. Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney.
Schramme A; Abdel-Bakky MS; Gutwein P; Obermüller N; Baer PC; Hauser IA; Ludwig A; Gauer S; Schäfer L; Sobkowiak E; Altevogt P; Koziolek M; Kiss E; Gröne HJ; Tikkanen R; Goren I; Radeke H; Pfeilschifter J
Kidney Int; 2008 Aug; 74(3):328-38. PubMed ID: 18480749
[TBL] [Abstract][Full Text] [Related]
7. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
Gutwein P; Schramme A; Sinke N; Abdel-Bakky MS; Voss B; Obermüller N; Doberstein K; Koziolek M; Fritzsche F; Johannsen M; Jung K; Schaider H; Altevogt P; Ludwig A; Pfeilschifter J; Kristiansen G
Eur J Cancer; 2009 Feb; 45(3):478-89. PubMed ID: 19070478
[TBL] [Abstract][Full Text] [Related]
8. Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases.
Schulte A; Schulz B; Andrzejewski MG; Hundhausen C; Mletzko S; Achilles J; Reiss K; Paliga K; Weber C; John SR; Ludwig A
Biochem Biophys Res Commun; 2007 Jun; 358(1):233-40. PubMed ID: 17467666
[TBL] [Abstract][Full Text] [Related]
9. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes.
Hundhausen C; Schulte A; Schulz B; Andrzejewski MG; Schwarz N; von Hundelshausen P; Winter U; Paliga K; Reiss K; Saftig P; Weber C; Ludwig A
J Immunol; 2007 Jun; 178(12):8064-72. PubMed ID: 17548644
[TBL] [Abstract][Full Text] [Related]
10. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.
Ludwig A; Hundhausen C; Lambert MH; Broadway N; Andrews RC; Bickett DM; Leesnitzer MA; Becherer JD
Comb Chem High Throughput Screen; 2005 Mar; 8(2):161-71. PubMed ID: 15777180
[TBL] [Abstract][Full Text] [Related]
11. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
Pruessmeyer J; Ludwig A
Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
[TBL] [Abstract][Full Text] [Related]
12. Human P2X7 receptor activation induces the rapid shedding of CXCL16.
Pupovac A; Foster CM; Sluyter R
Biochem Biophys Res Commun; 2013 Mar; 432(4):626-31. PubMed ID: 23428418
[TBL] [Abstract][Full Text] [Related]
13. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
[TBL] [Abstract][Full Text] [Related]
14. Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells.
Ebsen H; Schröder A; Kabelitz D; Janssen O
PLoS One; 2013; 8(10):e76853. PubMed ID: 24130797
[TBL] [Abstract][Full Text] [Related]
15. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
16. Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion.
Barlic J; Zhu W; Murphy PM
J Immunol; 2009 Jun; 182(12):7928-36. PubMed ID: 19494317
[TBL] [Abstract][Full Text] [Related]
17. Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.
Mezyk-Kopeć R; Bzowska M; Stalińska K; Chełmicki T; Podkalicki M; Jucha J; Kowalczyk K; Mak P; Bereta J
Cytokine; 2009 Jun; 46(3):309-15. PubMed ID: 19346138
[TBL] [Abstract][Full Text] [Related]
18. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy.
Abu El-Asrar AM; Nawaz MI; Ahmad A; De Zutter A; Siddiquei MM; Blanter M; Allegaert E; Gikandi PW; De Hertogh G; Van Damme J; Opdenakker G; Struyf S
Front Immunol; 2020; 11():601639. PubMed ID: 33552057
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity.
Gooden MJ; Wiersma VR; Boerma A; Leffers N; Boezen HM; ten Hoor KA; Hollema H; Walenkamp AM; Daemen T; Nijman HW; Bremer E
Br J Cancer; 2014 Mar; 110(6):1535-44. PubMed ID: 24518602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
